Halneuron® is WEX’s primary asset under development. Halneuron’s active pharmaceutical ingredient is Tetrodotoxin (“TTX”), a small molecule known to block voltage-gated sodium channels on neurons and prevents pain by inhibiting the initiation and conduction of nerve impulses in the peripheral nervous system which is associated with pain.
Halneuron is administered by subcutaneous injection and has been tested on over 500 people to date. Halneuron and TTX has been tested on patients with moderate to severe cancer pain as well as patients with chemotherapy-induced neuropathic pain and clinical data to date has shown varying degrees and duration of pain relief.
Halneuron is in Phase III clinical development for the treatment of cancer related pain and will commence Phase III clinical development for chemotherapy induced neuropathic pain.
Halneuron as an alternative to narcotics and opioid pain medication
The current gold standard for moderate to severe pain treatment are opioids. However, opioids have limitations and serious risks associated with continued use including respiratory, gastrointestinal and central nervous system side effects. Over time, opioids can become ineffective and expose patients to risks of addiction and tolerance.
Clinical data has shown Halneuron provides pain relief in certain moderate to severe pain conditions without the opioid side effects. Halneuron has an acceptable safety profile with no evidence of addiction and build up of tolerance. Some patients have demonstrated a long duration of pain relief as well as a meaningful reduction in their opioid consumption.